Maternal Inheritance of a Pathogenic MT-ND1 Mutation Causes Mitochondrial Dysfunction and Spermatogenic Failure in Men

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorThe Third Affiliated Hospital of Guangzhou Medical University

About this trial

Idiopathic non-obstructive azoospermia and cryptozoospermia are severe forms of male infertility in which sperm production is absent or extremely low and the cause is often unknown. This retrospective observational study examined whether mitochondrial DNA variants, particularly the MT-ND1 m.3700G\>A variant, are associated with impaired sperm production in Chinese men.

Existing clinical records and available biospecimens from affected men, eligible family members, and fertile controls were analyzed to assess familial inheritance patterns, the frequency of the variant, and its association with infertility phenotypes. No study-related treatment or intervention was provided to human participants.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Men with idiopathic non-obstructive azoospermia or cryptozoospermia.

Male patients undergoing a clinically indicated testicular biopsy, testicular sperm aspiration (TESA), microdissection testicular sperm extraction (micro-TESE), or a related clinical procedure, when residual clinical specimens are available.

Comparison participants with normal spermatogenesis, including men with obstructive azoospermia and men undergoing sperm retrieval or testicular tissue evaluation for clinical reasons.

Selected relatives and spouses of enrolled patients, when needed for genetic segregation analysis and determination of variant origin.

Disqualifiers

For the idiopathic non-obstructive azoospermia or cryptozoospermia cohort, azoospermia with an established alternative cause, including chromosomal abnormalities, Y-chromosome microdeletions, testicular tumors, severe trauma, prior radiotherapy or chemotherapy, or confirmed infection.

Incomplete clinical data or inability to obtain informed consent.

Biospecimens that do not meet quality requirements for the planned analyses.

Trial population

Participants were selected from men receiving care at the Reproductive Medicine Center of the Third Affiliated Hospital of Guangzhou Medical University. The study population included men with idiopathic non-obstructive azoospermia or cryptozoospermia identified through clinical records and available biospecimens; men with normal spermatogenic function or obstructive azoospermia who served as comparison participants; and, when needed, available first-degree relatives and spouses for family-based genetic analyses. Testicular tissue was obtained only from residual specimens following clinically indicated testicular biopsy, TESA, or micro-TESE procedures.

Trial design

Design model

Family-based

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

1,200 Participants
are grouped into 3 trial groups
Group A: INA/C Patients
Group B: Fertile Controls
Group C: Family Members

Trial outcomes

Primary outcomes

1

Detection and Familial Segregation of the MT-ND1 m.3700G>A Variant

Detection of the MT-ND1 m.3700G\>A mitochondrial DNA variant by sequencing in available biological samples, with assessment of its distribution and maternal segregation among affected male family members, unaffected relatives, unrelated patients with idiopathic non-obstructive azoospermia or cryptozoospermia, and fertile controls.

Time frame
Baseline (single genetic testing assessment at enrollment)

Secondary outcomes

1

Clinical Classification of Idiopathic Non-obstructive Azoospermia or Cryptozoospermia

Affected participants were classified as having idiopathic non-obstructive azoospermia or cryptozoospermia according to the clinical diagnosis recorded after routine semen analyses and standard clinical evaluation.

Time frame
Baseline (single clinical classification based on pre-enrollment clinical records)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.